Optimi Health Corp. (OPTH) Form 6-K — Sep 23, 2026
Optimi Health completed and quality-released a cGMP batch of 5mg naturally derived psilocybin capsules manufactured at its Princeton, B.C. facility under a Health Canada Drug Establishment Licence. The same batch supplies both a Health Canada-authorized Phase 2 open-label trial of psilocybin-assisted therapy in major depressive disorder (up to 200 participants, dosing expected complete by end of 2027) and commercial customers — licensed Australian clinics treating treatment-resistant depression under the TGA Authorised Prescriber Scheme with payer reimbursement.
Key figures
- Clinicians trained
- more than 750
- Commercial supply start
- 2025
- Phase2 trial participants
- up to 200
- Dosing completion expected
- end of 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.